Stock listing
Biocardia, Inc.
Selected listing: A40D1S · LS · EUR · DE
Biocardia, Inc. (Lang & Schwarz: A40D1S), Health Technology. Latest release Oct 7, 2026: BioCardia Presents CardiAMP HF II Trial Design at Heart Failure…
- Ticker
- Lang & Schwarz: A40D1S
- Asset type
- Stock
- Sector
- Health Technology
- Industry
- Biotechnology
- Exchange
- Lang & Schwarz
- Currency
- EUR
Latest news from Biocardia, Inc.
BioCardia Presents CardiAMP HF II Trial Design at Heart Failure Society of America Annual Scientific Meeting
October 6, 2026
BioCardia Files Revised De Novo Pre-Submission for FDA Approval of Helix™ Catheter
October 1, 2026
BioCardia Confirms Timing and Provides Update on FDA Helix Pre-Submission and PMDA CardiAMP HF Shonin Submission
September 23, 2026
BioCardia to Present CardiAMP Regulatory and Corporate Progress at H.C. Wainwright 28th Annual Global Investment Conference
September 10, 2026
BioCardia Announces FDA Confirms Helix Transendocardial Delivery Catheter Meeting Minutes Supporting Follow-On De Novo Pre-Submission for Approval
August 24, 2026
Events
Research Biocardia, Inc.
Alternate listings
BCDA:NASDAQ
US · USD
Alternate listing for Biocardia, Inc.; the primary context on this page is A40D1S:LS.
BCDA:BOATS
US · USD
Alternate listing for Biocardia, Inc.; the primary context on this page is A40D1S:LS.
6JU0:FWB
DE · EUR
Alternate listing for Biocardia, Inc.; the primary context on this page is A40D1S:LS.
6JU0:GETTEX
DE · EUR
Alternate listing for Biocardia, Inc.; the primary context on this page is A40D1S:LS.